Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02910700 · ClinicalTrials.gov registry record · Phase 2

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

A Phase 2 study of Metastatic Melanoma and Metastatic Malignant Neoplasm in the Brain, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
52
Enrollment target
1
Study location

NCT02910700: Active Phase 2 study of Metastatic Melanoma and Metastatic Malignant Neoplasm in the Brain, sponsored by M.D. Anderson Cancer Center.

NCT02910700 is a Phase 2 study of Metastatic Melanoma and Metastatic Malignant Neoplasm in the Brain that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02910700, a Phase 2 study of Metastatic Melanoma and Metastatic Malignant Neoplasm in the Brain, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Trametinib, dabrafenib, encorafenib, and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib may work better in treating patients with BRAF-mutated melanoma.

Primary Outcome

The ORR for each treatment group will be computed along 95% credible intervals.

Conditions Studied

Metastatic Melanoma Metastatic Malignant Neoplasm in the Brain Unresectable Melanoma Stage IV Cutaneous Melanoma AJCC v6 and v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Nivolumab
  • DRUG Binimetinib
  • DRUG Dabrafenib
  • DRUG Encorafenib

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2016-12-09
Est. Completion 2027-12-08
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT02910700 still lists

NCT02910700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (37% lower).

The record links to 8 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02910700 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02910700 about?

NCT02910700 is a clinical study titled "Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma". This phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable)...

What is the current status of trial NCT02910700?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2016-12-09. Estimated completion is 2027-12-08.

What conditions does trial NCT02910700 study?

This clinical trial studies the following conditions: Metastatic Melanoma, Metastatic Malignant Neoplasm in the Brain, Unresectable Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IIIC Cutaneous Melanoma AJCC v7.

What interventions are being tested in trial NCT02910700?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Binimetinib (DRUG), Dabrafenib (DRUG), Encorafenib (DRUG).

Who is sponsoring clinical trial NCT02910700?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02910700 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02910700's enrollment target sits among peer trials

52 33rd of 91 higher than 57 of 91 other Metastatic Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02910700, the US trial registry maintained by the National Library of Medicine. NCT02910700 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.